Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-42411)
the ministère de l’Enseignement supérieur, de la Recherche, de la Science et de la Technologie (MESRST) of the government of Quebec ((2012DFA30850))
Beijing Municipal Science & Technology Commission ((D131100005313004, D131100005313005))
Received: 12 May 2017
Accepted: 15 December 2017
First Online: 18 January 2018
Ethics approval and consent to participate
: Informed consent has been obtained from all participants and the study received ethical approval from The Capital Medical School in Beijing and McGill University (IRB Study Number A02-M34-13B).
: Participants/patients have given their consent for their data to be published in the report.
: The authors declare that MS, YZ, SP, and NL have applied for patent protection, MS has equity in HKG epitherapeutics and Montreal epiterapia, and DC has equity in Montreal epiterapia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.